which promote tumor growth and suppress the immune response5. CD40 is expressed on several antigen presenting cells (APCs) and agonistic CD40 antibodies (αCD40) have broad immunostimulatory effects. Indeed, αCD40 can polarize macrophages towards a tumor-suppressive profile and enhance antigen presentat...
Sandin L C, Totterman T H, Mangsbo S M. Local immunother⁃ apy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer[J]. Oncoimmunology, 2014, 3(1): e27400.
Clinically relevant TNFR agonists, comprising mAbs and recombinant natural ligands, exhibit a range of antitumor activities in cancer patients. To dissect the molecular mechanisms underlying such differential TNFR activation, we first investigated CD40 as a paradigm and explored receptor clustering on Jurkat...
Agonistic monoclonal antibodies (mAbs) targeting the costimulatory receptor CD137 enhance antibody-dependent cell-mediated cytotoxicity by natural killer (NK) cells and proliferation, functional activity, and survival of T cells.1 Based on these functions and other pre-clinical studies,1, 2, 3, 4,...
Creative Biolabshas successfully isolated and developed a series of immune agonistic/antagonistic antibodies to a panel of receptors, including the tumor necrosis factor (TNF) receptor superfamily, CD137 (4-1BB), CD134 (OX40), CD27, CD28, CD40, PD1/PD-L1 and so on. For more information, ...
· Karin Loré1,2 Received: 20 February 2023 / Revised: 11 May 2023 / Accepted: 1 June 2023 / Published online: 23 June 2023 © The Author(s) 2023 Abstract Targeting CD40 by agonistic antibodies used as vaccine adjuvants or for cancer immunotherapy is a strategy to stimulate ...
Antibodies specific for TNFRSF receptors that bind soluble ligands without getting properly activated generally act as strong agonists upon FcγR binding. Systematic analyses revealed that the FcγR dependency of such antibodies to act as potent agonists
In recently designed immunomodulatory approaches, CD40-targeting agonist monoclonal antibodies (mAbs) are used to enhance the ability of the immune system to recognize and destroy cancer cells. Respective pre-clinical studies have shown that agonistic CD40 mAb can activate APC and promote antitumor T-...
“Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells” Cancer Gene Therapy, 1998, 5(3):163-175. Cragg, et al. “Signaling antibodies in cancer therapy” Current Opinion in Immunology, Oct. 1999, 11(5):541...
Furthermore, agonists of T cell costimulatory molecules (CD40, 4-1BB, OX40) play an additional anti-cancer role to that of checkpoint blocking in combined therapy and serve also as adjuvant/neoadjuvant/induction therapy to conventional cancer treatments, such as tumor resection and radio- and ...